PREDICT-Dementia

Fluid and imaging biomarkers to improve differential diagnosis across dementias and to predict pathological subtypes and disease progression within the FTLD-spectrum. - PREDICT-Dementia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58559

Enrollment

275

Registered

2025-12-11

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frontotemporal dementia (FTD), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), primary progressive aphasia (PPA), corticobasal syndrome (CBS), Alzheimer’s Disease (AD) Frontotemporal dementia (FTD)

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age = 18 years One of the following clinical conditions or genetic statuses: Behavorial variant of FTD Phenocopy FTD Progressive supranuclear palsyCorticobasal syndromePrimary progressive aphasia Alzheimer's diseasePresymptomatic carrier of a pathogenic variant in GRN, C9orf72 or MAPT, or at 50% risk for one of these variants Known, healthy control (non-carriers)3.  Full clinical and neuropsychological assessment performed. 4. Willing and able to provide written informed consent. 5. Availability of an identified informant who is willing to participate in the study. 

Exclusion criteria

Exclusion criteria: Contraindications for completing any mandatory part of the study protocol Other medical or psychiatric illnesses that would interfere with completing assessments Pregnancy Diminished capacity

Design outcomes

Primary

Measure	Time frame
The primary study endpoint is the diagnostic accuracy of a multimodal model combining different biomarkers (e.g., imaging, fluid biomarkers) and clinical data for distinguishing FTD-TDP from FTLD-Tau. Diagnostic performance will be quantified using the area under the Receiver Operating Characteristic curve (AUC) and compared to models based on individual biomarkers.	—

Secondary

Measure	Time frame
The secondary endpoint is the AUC of multimodal models in differentiating between FTLD and other (non-)neurodegenerative diseases. In addition, disease progression will be evaluated and time to conversion in presymptomatic carriers will be predicted using biomarker data. The socioeconomic burden of FTD will be assessed by calculating direct and indirect costs for patients and their caregivers, expressed in euros or pounds, based on healthcare utilization, informal care, and productivity loss. In addition, this endpoint will evaluate the effect of earlier diagnosis on patient burden and caregiver outcomes.	—

Measure

Time frame

The secondary endpoint is the AUC of multimodal models in differentiating between FTLD and other (non-)neurodegenerative diseases. In addition, disease progression will be evaluated and time to conversion in presymptomatic carriers will be predicted using biomarker data. The socioeconomic burden of FTD will be assessed by calculating direct and indirect costs for patients and their caregivers, expressed in euros or pounds, based on healthcare utilization, informal care, and productivity loss. In addition, this endpoint will evaluate the effect of earlier diagnosis on patient burden and caregiver outcomes.  

—

Countries

Finland, Germany, Italy, Netherlands, Spain

Contacts

Public ContactH. Seelaar

Erasmus MC, Universitair Medisch Centrum Rotterdam

h.seelaar@erasmusmc.nl0650190462

Outcome results